“Our Q4 was successful and highly productive. We generated robust revenue growth driven by healthy VTE procedure volumes, continued traction across our emerging therapies and another quarter of strong international performance,” said CEO Drew Hykes. “In addition, we made solid progress across all three of our RCTs and began launching LimFlow in the U.S. Looking ahead, we are focused on continuing to deliver strong growth and progressing towards operating profitability. Most importantly, we remain fully committed to our mission of driving better outcomes for our patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical price target raised to $70 from $65 at Truist
- Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Inari Medical management to meet virtually with BTIG
- Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)
- Inari Medical announces first patient enrolled in PEERLESS II study
